410 related articles for article (PubMed ID: 30026228)
1. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.
Zhang J; Wu T; Simon J; Takada M; Saito R; Fan C; Liu XD; Jonasch E; Xie L; Chen X; Yao X; Teh BT; Tan P; Zheng X; Li M; Lawrence C; Fan J; Geng J; Liu X; Hu L; Wang J; Liao C; Hong K; Zurlo G; Parker JS; Auman JT; Perou CM; Rathmell WK; Kim WY; Kirschner MW; Kaelin WG; Baldwin AS; Zhang Q
Science; 2018 Jul; 361(6399):290-295. PubMed ID: 30026228
[TBL] [Abstract][Full Text] [Related]
2. USP13 promotes deubiquitination of ZHX2 and tumorigenesis in kidney cancer.
Xie H; Zhou J; Liu X; Xu Y; Hepperla AJ; Simon JM; Wang T; Yao H; Liao C; Baldwin AS; Gong K; Zhang Q
Proc Natl Acad Sci U S A; 2022 Sep; 119(36):e2119854119. PubMed ID: 36037364
[TBL] [Abstract][Full Text] [Related]
3. ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
Zhu L; Ding R; Yan H; Zhang J; Lin Z
Cell Death Dis; 2020 May; 11(5):337. PubMed ID: 32382017
[TBL] [Abstract][Full Text] [Related]
4. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
5.
Yao X; Tan J; Lim KJ; Koh J; Ooi WF; Li Z; Huang D; Xing M; Chan YS; Qu JZ; Tay ST; Wijaya G; Lam YN; Hong JH; Lee-Lim AP; Guan P; Ng MSW; He CZ; Lin JS; Nandi T; Qamra A; Xu C; Myint SS; Davies JOJ; Goh JY; Loh G; Tan BC; Rozen SG; Yu Q; Tan IBH; Cheng CWS; Li S; Chang KTE; Tan PH; Silver DL; Lezhava A; Steger G; Hughes JR; Teh BT; Tan P
Cancer Discov; 2017 Nov; 7(11):1284-1305. PubMed ID: 28893800
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss.
Liu X; Simon JM; Xie H; Hu L; Wang J; Zurlo G; Fan C; Ptacek TS; Herring L; Tan X; Li M; Baldwin AS; Kim WY; Wu T; Kirschner MW; Gong K; Zhang Q
Mol Cell; 2020 Mar; 77(6):1294-1306.e5. PubMed ID: 32023483
[TBL] [Abstract][Full Text] [Related]
7. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.
Pantuck AJ; An J; Liu H; Rettig MB
Cancer Res; 2010 Jan; 70(2):752-61. PubMed ID: 20068166
[TBL] [Abstract][Full Text] [Related]
9. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma.
Ma X; Shen D; Li H; Zhang Y; Lv X; Huang Q; Gao Y; Li X; Gu L; Xiu S; Bao X; Duan J; Zhang X
Urol Oncol; 2015 Apr; 33(4):169.e1-11. PubMed ID: 25700976
[TBL] [Abstract][Full Text] [Related]
11. Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance.
Razafinjatovo C; Bihr S; Mischo A; Vogl U; Schmidinger M; Moch H; Schraml P
BMC Cancer; 2016 Aug; 16():638. PubMed ID: 27530247
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.
Vanharanta S; Shu W; Brenet F; Hakimi AA; Heguy A; Viale A; Reuter VE; Hsieh JJ; Scandura JM; Massagué J
Nat Med; 2013 Jan; 19(1):50-6. PubMed ID: 23223005
[TBL] [Abstract][Full Text] [Related]
13. VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2.
Gao YH; Wu ZX; Xie LQ; Li CX; Mao YQ; Duan YT; Han B; Han SF; Yu Y; Lu HJ; Yang PY; Xu TR; Xia JL; Chen GQ; Wang LS
Nat Commun; 2017 Jun; 8():15337. PubMed ID: 28643803
[TBL] [Abstract][Full Text] [Related]
14. Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma.
Zhao Z; Chen C; Lin J; Zeng W; Zhao J; Liang Y; Tan Q; Yang C; Li H
Mol Med Rep; 2016 Sep; 14(3):2785-90. PubMed ID: 27485825
[TBL] [Abstract][Full Text] [Related]
15. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
16. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
[TBL] [Abstract][Full Text] [Related]
18. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
19. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.
An J; Rettig MB
Mol Cell Biol; 2005 Sep; 25(17):7546-56. PubMed ID: 16107702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
